SSP-30 - 225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation

RODAK, Magdalena; DEKEMPENEER, Yana; WOJEWODZKA, Maria; LAHOUTTE, Tony; BRUCHERTSEIFER, Frank; MORGENSTERN, Alfred; D’HUYVETTER, Matthias; PRUSZYNSKI, Marek

doi:10.1016/S0969-8051(21)00317-6

Human Epidermal Growth Factor Receptor type 2 (HER2) overexpression cause more aggressive form of cancer, metastatic activity and chemo-resistance. Nanobodies (Nbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and Targeted Radionuclide Therapy (TRT). Therefore, HER2-targeting nanobodies are very attractive vectors for TRT, especially when labeled with α-particle emitters, due to their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and ease of tumor penetration. The goal of this study was to evaluate the therapeutic potential of the anti-HER2 Nb 2Rs15d labeled with 225Ac.

RODAK Magdalena; DEKEMPENEER Yana; WOJEWODZKA Maria; LAHOUTTE Tony; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; D’HUYVETTER Matthias; PRUSZYNSKI Marek;

2022-03-28

ELSEVIER SCIENCE INC

JRC124540

0969-8051 (online),

https://www.sciencedirect.com/science/article/pii/S0969805121003176, https://publications.jrc.ec.europa.eu/repository/handle/JRC124540,

10.1016/S0969-8051(21)00317-6 (online),

Language	Citation

Name	Country	City	Type

Datasets

ID	Title	Public URL

Dataset collections

ID	Acronym	Title	Public URL

Scripts / source codes

Description	Public URL

Additional supporting files

File name	Description	File type

Items published in the JRC Publications Repository are protected by copyright, with all rights reserved, unless otherwise indicated. Additional information: https://ec.europa.eu/info/legal-notice_en#copyright-notice